ReviewCureus2021
Medical Cannabis, Headaches, and Migraines: A Review of the Current Literature.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.Headache · 2026Trial
- In silico receptor binding and ex vivo nasal epithelial membrane permeation studies of selected phytocannabinoids.Journal of cannabis research · 2026Article
- Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies.Cells · 2026Review
- Differential inhibitory effects of endocannabinoids on neuronal firing of mouse meningeal afferents.The journal of headache and pain · 2025Article
- Enhancement of the endocannabinoid system through monoacylglycerol lipase inhibition relieves migraine-associated pain in mice.The journal of headache and pain · 2025Article
- Natural Products Derived from Cannabis sativa for Pain Management.Handbook of experimental pharmacology · 2025Review
- Therapeutic use of medical Cannabis in neurological diseases: a clinical update.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Article
- The Antioxidant and Neuroprotective Potential of Leaves and Inflorescences Extracts of Selected Hemp Varieties Obtained with scCOAntioxidants (Basel, Switzerland) · 2023Article
- Looking Back, Moving Forward in Pain Medicine.Cureus · 2023Review
- Article
- Exploratory Factor Analysis of Medical Students' Perceptions of Medical Cannabis Scale.Cureus · 2022Article
- Article
- Clinical Evidence of Cannabinoids in Migraine: A Narrative Review.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis has been long used since ancient times for both medical and recreational use. Past research has shown that cannabis can be indicated for symptom management disorders, including cancer, chronic pain, headaches, migraines, and psychological disorders (anxiety, depression, and post-traumatic stress disorder). Active ingredients in cannabis that modulate patients' perceptions of their conditions include Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.